首頁 › 乳癌 › 猶他州 › Salt Lake City
Salt Lake City, UT 的 乳癌 臨床試驗
27 項針對 乳癌 的研究正在 Salt Lake City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
招募中3 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
招募中3 期
- Clinical Trial Site, Salt Lake City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- Utah Cancer Specialists, Salt Lake City
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
招募中2 期
- Huntsman Cancer Institute, Salt Lake City
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
招募中1/2 期
- University of Utah Huntsman Cancer Institute, Salt Lake City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
招募中3 期
- Huntsman Cancer Hospital at the University of Utah, Salt Lake City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- Farmington Health Center, Farmington · 距離 15 英里
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
招募中2 期
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
招募中3 期
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
招募中3 期
- University of Utah - Huntsman Cancer Institute, Salt Lake City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
招募中2 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
招募中3 期
- Huntsman Cancer Institute, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
招募中
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- Utah Cancer Specialists-Salt Lake City, Salt Lake City
- LDS Hospital, Salt Lake City
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
招募中1/2 期
- START Center for Cancer Care - Mountain Region, Salt Lake City
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
招募中早期第 1 期
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Improving Care for Rural Patients With Solid Tumors
招募中
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
招募中2 期
- Huntsman Cancer Institute/University of Utah, Salt Lake City
SAVE Trial: SAfe Opioid Use Video Education
招募中
- University of Utah Huntsman Cancer Institute, Salt Lake City
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
招募中歡迎健康志工
- Huntsman Cancer Institute/ University of Utah, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Salt Lake City
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
招募中3 期
- Huntsman Cancer Institute at University of Utah, Salt Lake City
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
招募中1 期
- University of Utah- Huntsman Cancer Center, Salt Lake City
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
招募中
- University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences, Salt Lake City
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Salt Lake City 的其他研究
- 非小細胞肺癌31 項研究
- 癌症（所有類型）27 項研究
- 大腸直腸癌22 項研究
- 肺癌21 項研究
- 黑色素瘤21 項研究
- 多發性骨髓瘤21 項研究
- 轉移性癌症20 項研究
- 卵巢癌19 項研究
- 肥胖症18 項研究
- 急性髓系白血病17 項研究
- 心臟衰竭17 項研究
- 前列腺癌15 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。